Cerbios-Pharma joins Global Reporting Initiative with Sustainability Report
Press Release | Cerbios-Pharma SA
MAY 05, 2016
Lugano, Switzerland: – High-tech CDMO Cerbios-Pharma SA (Cerbios) has announced that it will publish its first Sustainability Report during 2016.
“Cerbios Pharma has started a process which will lead to the publishing of its first Sustainability Report, following the guidelines of the Global Reporting Initiative, GRI G4,” the company announced.
“As a private, family owned company, Cerbios Pharma believes in being a good corporate citizen,” commented Andrea Tam, Chief Commercial Officer.
“Our culture has always been based on strong ethical values,” said Tam.
“So pursuing a triple bottom line of financial, social and environmental performance is a natural evolution for our organization,” he added.
“Cerbios Pharma wants to continue to be competitive in a business environment that is rapidly evolving,” said Business Development Manager Mara Camillo.
Formal impacts assessment
“This now entails a more formal approach towards the management of the impacts our activities have on our environment, on our society, and on all our stakeholders,” she explained.
The company is now developing reporting and measurement tools that will assess its sustainability performance, measuring impacts and providing Cerbios with improved identification of areas where it excels and those with room for improvement.
“We know that Cerbios-Pharma makes an important contribution to society, the environment, the local economy and to several stakeholders’ groups: with these tools, we will be able to measure such contribution and to become more sustainable, every day,” said Mr Tam.
Cerbios-Pharma SA is a privately held company located in Lugano, Switzerland, that specializes in the development and manufacture of both chemical and biological APIs for its partners world-wide. Formed in 1994 by the merger of Bioferment SA (founded in 1976) and Sapec SA (founded in 1979), Cerbios specializes in the development and production of high potency active pharmaceutical ingredients (HPAPIs) in the area of fine chemicals and biologicals.
Cerbios Chemical Division offers exclusive, third-party manufacturing services for HPAIs while Biological Division produces monoclonal antibodies, recombinant proteins and pharma probiotics.
Cerbios provides full CMC support to its worldwide partners, including the supply of cGMP clinical batches, registration/validation material and commercially manufactured APIs. Paramount to this is the ability to supply all of the technical documentation and support necessary for a successful registration. Cerbios’ commercial products are marketed worldwide but primarily in Europe, USA, Japan and India.
Mara Camillo, Business Development Manager, Cerbios-Pharma SA
Tel: +41 91 9856556
Click on Cerbios-Pharma joins Global Reporting Initiative with Sustainability Report for more information.
Click on Cerbios-Pharma to contact the company directly.